April 1, 2003 - Preliminary Results for 14 month period ended 31 December 2002
Cyprotex PLC, a drug discovery technology and information company, today reports its preliminary results for the 14 months to 31 December 2002.
revenue for the 14 months to 31 December 2002 was £647,770 against £98,614 for the preceding 7 months to 31 October 2001
losses for the period were £3,357,182 against £386,752 for the preceding 7 months to 31 October 2001
expenditure reflects investments made to develop the business
12 deals signed including contracts with AstraZeneca, Astex Technology and Roche
moved to a customised laboratory and office facility in the UK delivering high throughput automated screening and in silico technology
Commenting on the results, John Nicholson, Chief Operating Officer of Cyprotex PLC, said:
"In common with other companies providing products to the life sciences sector, Cyprotex has faced a tough and challenging environment in its first trading period as a public company. However, the Group has continued to focus on the development and effective delivery of its core technologies whilst highlighting to the market the technical and cost benefits of Cyprotex's products. The Board is encouraged by the level of interest in its products from major pharmaceutical and international biotech companies."
Download Cyprotex Preliminary Results Including Financial Reports
For further information, please contact:
John Nicholson, Chief Operating Officer
Tel: +44 (0) 1625 505 100
Henry Harrison-Topham / Heather Salmond
Tel: +44 (0) 20 7444 4140